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Workshop on Best Practices
and the Need for HarmonizationA workshop addressing regulation of clinical implementation of stem cell therapies preceded the ISSCR 8th
Annual Meeting, cosponsored by the International Society for Stem Cell Research, the California Institute for
Regenerative Medicine and the International Society for Cellular Therapy.Introduction
Stem cell therapies offer enormous potential for the treatment of
a wide range of diseases and injuries including neurodegenera-
tive diseases, cardiovascular disease, diabetes, arthritis, spinal
cord injury, stroke, and burns. However, the regenerative and
differentiation capacity and other aspects of stem cells that
make them attractive as treatments also create challenges for
the establishment of criteria to ensure development of safe and
effective therapies. Although emerging regulatory frameworks
seek to define these criteria, the absence of legislation or
enforcement, desperation for cures and media hype spur
a medical tourism industry that exploits differences or gaps in
regulatory oversight.
In particular, media hype has created a cottage industry of
companies that are selling stem cell treatments that have not
been tested in clinical trials as required in certain countries
such as the United States (US) and Europe. As such, these
companies may place uninformed and often desperate patients
at risk. On the other hand, companies that do not rush to market
but instead set out to first test their products in clinical trials are
faced with a myriad of regulatory requirements that are often
uncertain or unclear in their application.
To address this situation, the International Society for Stem
Cell Research (ISSCR) is working to establish a roadmap that
protects patients and fosters the dramatic innovation in the
stem cell field. Regulatory frameworks to achieve this objective
were explored on June 15, 2010 in a workshop, which featured
eminent scientists and regulators from around the globe. The
workshop served as an international forum for discussion of
the challenges pertaining to development of stem cell regula-
tions and the need for harmonization.
Challenges to Stem Cell Therapy Development
and Regulation
Stem cell-based products present a unique regulatory challenge
because standard pharmaceutical paradigms do not wholly
apply and accordingly, stem cell therapies do not neatly fit into
current regulatory categories. As a result, regulatory require-
ments are often unclear in their application and create uncer-
tainty.
To better understand how stem cell therapies are faring in this
regulatory environment, the California Institute of Regenerative
Medicine (CIRM) performed a qualitative survey of their stake-
holders and presented it at this workshop. The salient conclusion
of the survey is that the relevant regulatory agency, the Food and
Drug Administration, USA (FDA), readily permits clinical trials ontransient cell therapies, but it is very difficult to get pluripotent or
nontransient (integrating) cell therapeutics into trials. Barriers to
the advancement of these therapies lie in both technical and
regulatory constraints.
Technical constraints include the need for extended vigilance
of integrating cells, as well as novel assays and predictive
animal models. In particular, given that regenerative stem cell
therapies are intended to persist lifelong in the host as part of
the therapeutic solution they provide, it will be critical to mini-
mize the presence of any residual undifferentiated cells. Thus,
purity threshold levels need to be established at the onset of
therapy and long-term patient monitoring will be required.
However, it is debatable whether the limit of detection available
today is sensitive enough for sufficiently rigorous tracking of
cells in vivo. Accordingly, there is a need for the development
of high resolution imaging, markers and extended monitoring
in different species to identify which ones are the most
predictive.
Another key finding of the CIRM survey is that regulatory
uncertainty creates delays in the clinical development of plurip-
otent and nontransient cell therapies. As the level of uncer-
tainty rises, development costs escalate and investment
dollars attenuate. Frustrated companies surveyed by CIRM
voiced key operational adjustments that could enhance regula-
tory predictability: early notification of newly formulated posi-
tions or guidance espoused by the FDA, more frequent and
consultative communication with the agency, and ability to
obtain as many binding decisions as possible for aspects of
preclinical and clinical programs. Some companies felt that
the risk-benefit evaluation should consider the cost to patients
of delaying development of new therapies that could treat
them.
There is a clear need for new research tools and regulatory
guidance to foster development of the types of stem cells that
are potentially the most therapeutically impactful.
International Oversight
The momentum of stem cell therapy advancement is outpacing
the speed of legislation and regulation. Nonetheless, govern-
ments, academia and the private sector are building frameworks
to lay the foundation for regulation (Table 1). These evolving
frameworks reflect unique cultural differences that give rise to
a spectrum of varying risk tolerances in stem cell research,
development and commercialization. Eminent scientists and
regulatory experts from around the globe outlined their positions,
pointing to some unique features of their regions.Cell Stem Cell 7, 451–454, October 8, 2010 ª2010 ISSCR 451
Table 1. Regulatory Frameworks by Region
Country Regulatory Framework Related Websites
Argentina Ministry of Health and Administration of Medications,
Foods, andMedical Technology (ANMAT) created Instituto
Nacional Central Unico Coordinador de Ablacion e
Implante (INCUCAI) in 2007 as an agency relating to the
use of human cells for implantation. In 2008, the Consorcio
de Investigacio´n en Celulas Madres (CICEMA) was
created to foster ties between industry, academia and the
clinic.
www.msal.gov.ar
www.anmat.gov.ar
www.incucai.gov.ar
www.cicema.org.ar/english/home_eng
China The Ministry of Health of the People’s Republic of China
(MOH) provides guidance on regulation of stem cell
therapies.
www.moh.gov.cn; http://eng.sfda.gov.cn/eng/
European Union The Advanced Therapy Medicinal Products (ATMP)
Regulation was adopted by the European Medicines
Agency (EMA) in 2007. Stem cell therapies are currently an
area of discussion within the Committee for Advanced
Therapies (CAT) created under the ATMP.
http://ec.europa.eu/health/human-use/advanced-therapies
www.ema.europa.eu
India The Indian Council for Medical Research (ICMR) created
the National Apex Committee for Stem Cell Research and
Therapy (NAC-SCRT), which is an interagency body
taskedwith the oversight of the research and development
of stem cell therapeutics.
www.icmr.nic.in
Japan The Japanese Ministry of Health, Labor and Welfare
(MHLW) drafted guidelines for development and approval
of novel medical products including adult stem cells.
Pluripotent cells are not yet addressed in the current
version of the guidelines.
www.mhlw.go.jp/english
United States
of America
The Center for Biologics Evaluation and Research (CBER),
Office of Cellular, Tissue and Gene Therapies (OCTGT) is
charged with the oversight of stem cell products. In 2005,
CBER-OCTGT issued guidance on cellular therapies in the
‘‘Tissue Rules’’ (CFR – 1271) and in 2008 provided
a briefing pertaining to hESC-related therapies.
www.fda.gov/BiologicsBloodVaccines/
CellularGeneTherapyProducts
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Stem cell therapies are not yet approved in Argentina; however,
to begin to build the infrastructure for their regulation, the
Ministry of Health and Administration of Medications, Foods,
and Medical Technology (ANMAT) created two units directed
toward cellular treatments. The first, Instituto Nacional Central
Unico Coordinador de Ablacion e Implante (INCUCAI), was
created by a resolution of the Ministry of Health in 2007 as an
agency relating to the use of human cells for implantation. The
second, Consorcio de Investigacio´n en Celulas Madres
(CICEMA), is a consortium created in 2008 with the objective
of studying the therapeutic potential of stem cells, fostering
ties between industry, academia, and the clinic and setting up
processes to develop these discoveries in a rigorous way.
China
The State Food and Drug Administration (sFDA) regulated
cellular therapies in China until 2009, when the sFDA became
part of the Ministry of Health (MoH). Accordingly, in the process
of absorbing the sFDA and establishing uniform policies to regu-
late cell transplants, the MoH is requiring certification of organ
transplant and cellular therapy centers and procedures by the
end of 2010. Although cell therapies are now centrally regulated
by MoH, there are ‘‘special administrative regions’’ (SAR) that
regulate their own medical care. These include Hong Kong,452 Cell Stem Cell 7, 451–454, October 8, 2010 ª2010 ISSCRShenzhen, and Tibet. In particular, the Hong Kong SAR has its
own Department of Health that approves clinical trials.
China currently permits autologous transplant of bone
marrow, off-label use of cord blood and fetal cell transplants.
As such, approved stem cell clinical trials are currently ongoing
in China. This includes a 400 patient phase 3 clinical trial in which
cord blood mononuclear cells are transplanted into patients with
chronic spinal cord injuries. The trial is randomized to oral lithium
or placebo and patients are followed for 1 year. Prior preclinical
animal studies were not conducted.
The European Union
The European Medicines Agency (EMA) regulatory framework
for stem cell-based therapies is complex and dynamic. In
2007, the EMA adopted the Advanced Therapy Medicinal Prod-
ucts (ATMP) Regulation. The ATMP comprises new medical
products based on genes (gene therapy), cells (cell therapy),
and tissues (tissue engineering) and allows for the creation of
novel committees and processes aimed at the development of
these new medical products.
In 2008, the ATMP established a multidisciplinary Committee
for Advanced Therapies (CAT) to assess products and track
related scientific developments. CAT consists of 22 experts
from national competent authorities; five members from the
Committee for Medicinal Products for Human Use (CHMP);
Cell Stem Cell
ISSCR: Committee Forumtwo patients; and two clinicians and alternates for all aforemen-
tioned positions. CAT is currently considering various aspects of
stem cell-based medicinal products and monthly meeting
reports are available on their website. The ATMP allows for
a centralized marketing authorization procedure with the aim of
leveraging the collective EU expertise while permitting country
to country differences with respect to the requirements for
entering into the clinic. Member states have the right to refuse
to market a product nationally on ethical grounds, so an
approved product might not be marketed in all EU/European
Economic Area (EEA) countries.
With respect to marketing of stem cell therapies, there are
commercially available products in the EU currently marketed
under old frameworks. These therapies are effectively grandfath-
ered under a transitional period that extends until 2011. Member
states have authority to allow or refuse marketing of these ther-
apies. It is important to note that the EMA does not support the
marketing of unlicensed stem cell therapies.
One especially unique feature of the ATMP that bears
mentioning is the recognition that a disproportionate share of
new medical products will be generated by smaller companies
and hospitals rather than by large pharmaceutical firms. To this
end, the ATMP provides incentives for small and medium-sized
enterprises, including scientific advice, special certification
procedures, and fee reductions.
India
Robust interest in stem cell treatments in India results from
a unique combination of three main drivers: (1) significant unmet
health needs; (2) high consumer demand from a large private
healthcare network; and (3) historical trust in alternative systems
of medicine, whichmay not be evidence based. This high level of
interest in stem cell treatments also engenders ample funding for
research and development of stem cell therapies through
venture capitalists and through the Department of Biotech-
nology, which supports 90% of the projects.
The building blocks for regulatory approval of stem cell thera-
pies are still in development. The Indian Council for Medical
Research (ICMR) formulated guidelines for stem cell research
in 2007. In particular, the ICMR has forbidden the use of embry-
onic cells for clinical treatment in its guidelines. However, these
guidelines have not yet been converted into law and thus it is ex-
pected, but not mandatory, to register all stem cell clinical trials.
While the regulatory system is still in development, there are
currently different mechanisms to regulate clinical translation,
variable criteria used by oversight bodies for protection for
human subjects and the ability to regulate practice of medicine
separate from research. To unify and streamline the process,
the National Apex Committee for Stem Cell Research and
Therapy (NAC-SCRT) was created in 2009. NAC-SCRT is an
interagency body created with the aim of effectively reviewing
and monitoring stem cell research in India.
Japan
TheMinistry of Health, Labor andWelfare (MHLW) has produced
a Guideline on Ensuring Quality and Safety of Products Derived
from Processed Human Cell and Tissues (MHLW Notification
#1314; Nov 26, 2000) as the basis for both the regulation of
stem cell clinical research as well as the promotion of regenera-
tive medicine. In this guideline, the definition of ‘‘stem cells’’
comprises tissue-derived human stem cells that are multipotentand self-renewing. It is noteworthy that embryonic stem cells
(ESCs) and induced pluripotent stem cells (iPSCs) are excluded
from these guidelines. The MHLW is currently in the process of
amending the guidelines to include ESCs and iPSCs.Meanwhile,
transplantation of ESCs is expressly prohibited. Also, the MHLW
has formed a committee that is working to amend the guidelines
to consider collaboration, manufacturing process, proof of
concept, safety assessment, and clinical safety management
of stem cell therapies.
United States
The FDA’s Center for Biologics Evaluation and Research (CBER),
Office of Cellular, Tissue and Gene Therapies (OCTGT) is
charged with the oversight of stem cell products as well as other
biological products including gene therapies, tumor vaccines
and immunotherapies. In 2005, CBER-OCTGT issued the
‘‘Tissue Rules’’ (21 CFR 1271), which form the basis for regula-
tion of all human cells, tissues, and cellular and tissue-based
products (HCT/Ps). Regarding stem cells specifically, in 2008
CBER-OCTGT generated guidance for ESC-based therapies
as well as considerations for preclinical safety testing and patient
monitoring.
Stem Cell Tourism
The absence of international harmonization of regulations and
robust enforcement has allowed stem cell tourism to take root.
The practice of traveling abroad for medical treatment does
not in itself present concern if patients are availing themselves
of treatments that are part of regulated trials or, where marketed,
have been established through clinical trials to be safe and effec-
tive. However, this is not always the case.
Stem cell clinics frequently advertise procedures on the
internet and promise to deliver therapeutic outcomes that are
simply not backed by scientific literature (Lau et al., 2008). In
some cases, large sums of money are charged and can range
from $20,000–$30,000 or more.
In response to aggressive marketing campaigns, the ISSCR
launched a newwebsite (www.closerlookatstemcells.org) based
on recommendations from the ISSCR’s Task Force on Unproven
Stem Cell Treatments (Taylor et al., 2010). The goal of the web-
site is to provide patients with information about stem cells per-
taining to stem cell treatments and to outline widely accepted
best practices in introducing new medicines into the clinic.
Beginnings of Harmonization
Although the stem cell industry may not be mature enough to
support the types of harmonization activities that we have seen
in the biotechnology field, regulators aremaking efforts to under-
stand one another’s approaches across borders. One particular
example of cooperation is the existing FDA-EMA ‘‘Cluster,’’
which expanded its scope in 2008 to include cell and gene ther-
apies after the creation of the ATMP regulation. A second
example is the role of the UK-based Economic and Social
Research Council (ESRC) in fostering the development of stem
cell regulations in Argentina.
Global harmonization efforts will ultimately need to accommo-
date nuances of cultural dissimilarities and risk appetites to
strike an acceptable balance between progress and safeguards.
There are several bodies that can play complementary roles in
this international effort, including the National Institute ofCell Stem Cell 7, 451–454, October 8, 2010 ª2010 ISSCR 453
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ISSCR: Committee ForumStandards and Technology (NIST), the Council for International
Organizations of Medical Sciences (CIOMS), and the Interna-
tional Conference on Harmonisation (ICH), as well as the
sponsors of the regulatory workshop, ISSCR, CIRM, and the
International Society for Cell Therapy.
Conclusions
The tenor of the regulatory workshop revealed a collective
commitment to an ambitious and complex therapeutic goal.
Key takeaways included (1) awareness of the need for legislation
andmore rigorous enforcement in some countries; (2) the impor-
tance of independent review and transparency—in particular,
the imperative to publish through a process of peer-review and454 Cell Stem Cell 7, 451–454, October 8, 2010 ª2010 ISSCRto report negative data; (3) desire to harmonize oversight mech-
anisms for consistency, simplicity and efficiency; (4) the need to
manage conflicts of interest; and (5) recognition of the medical
needs of patients and the responsibility to move forward
together as rapidly and as safely as possible.REFERENCES
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